SCHEMBL2618803

SCHEMBL2618803

NC(=O)c1ccncc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.55
▸ SIRT3 Q9NTG7 2/20 0.55
▸ CDC7 O00311 3/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ KDM4C Q9H3R0 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KDM6B O15054 1/20 0.47
▸ KDM4A O75164 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ KDM4D Q6B0I6 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ DGAT1 O75907 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ LOXL2 Q9Y4K0 1/20 0.44
▸ F7 P08709 1/20 0.44
▸ F3 P13726 1/20 0.44
▸ SARM1 Q6SZW1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30298673 1.00 TDP1 (0.55) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL1135627 0.83 SIRT3 (0.60) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL30475729 0.81 KDM4C (0.42) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL29578794 0.81 KDM4C (0.59) TDP1KDM4EALDH1A1KDM4CMEN1
SCHEMBL82604 0.81 KDM4C (0.59) TDP1KDM4EALDH1A1KDM4CMEN1
SCHEMBL1330970 0.80 TDP1 (0.67) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL1687197 0.80 TDP1 (0.67) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL25201864 0.79 KDM4C (0.42) TDP1SIRT3CDC7KDM4EALDH1A1
Hydrochloric Acid SCHEMBL1027857 0.79 KDM4C (0.57) TDP1KDM4EALDH1A1KDM4CMEN1
SCHEMBL724581 0.79 ALDH1A1 (0.52) TDP1SIRT3CDC7KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180185-B2 Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof HK INNO.N CORPORATION (KR) 2024-12-31 — — US claimed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 — — US claimed
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES GRUENENTHAL GMBH (DE) 2023-01-26 — — US claimed
US-20220009902-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK INNO.N CORPORATION (KR) 2022-01-13 — — US claimed
CN-103687846-A Benzylamine derivatives as inhibitors of plasma kallikrein KALVISTA PHARMACEUTICALS LTD 2014-03-26 — — CN claimed
EP-1984337-A2 VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 — — EP claimed
WO-2007087443-A2 VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 — — WO claimed
EP-1068187-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 2001-01-17 — — EP claimed
WO-1999051580-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 1999-10-14 — — WO claimed
US-12534456-B2 Heterocyclyl pyridines as novel fungicides BAYER AKTIENGESELLSCHAFT (DE) 2026-01-27 — — US disclosed
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) 2025-04-17 — — US disclosed
US-12180185-B2 Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof HK INNO.N CORPORATION (KR) 2024-12-31 — — US disclosed
EP-4465988-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS Calcimedica, Inc. (US) 2024-11-27 — — EP disclosed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 — — US disclosed
CN-101863829-A Synthesis method of 3-fluorine-4-aminopyridine JIAXING SANGDIYA LIANYOU PHARMACY CO LTD 2010-10-20 — — CN disclosed
EP-1984337-A2 VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2008-10-29 — — EP disclosed
EP-1940835-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2008-07-09 — — EP disclosed
WO-2007087443-A2 VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-08-02 — — WO disclosed
WO-2007036733-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-05 — — WO disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999699-B2 Substituted pyrazole amides SCN8A, SCN1A, SCN7A TDP1 3512/4885SIRT3 288/4885CDC7 3949/4885
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SGK1, HYPK, PCK1 TDP1 1421/4885SIRT3 2300/4885CDC7 392/4885
US-12180185-B2 Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof MAP3K20, MAP3K1, MAP3K15 TDP1 1806/4885SIRT3 4295/4885CDC7 500/4885
US-12534456-B2 Heterocyclyl pyridines as novel fungicides CBR1, CBR3, NOX1 TDP1 2453/4885SIRT3 852/4885CDC7 534/4885
US-20220009902-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF MAP3K20, MAP3K1, MAP3K15 TDP1 1650/4885SIRT3 4211/4885CDC7 462/4885
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES SCN8A, SCN1A, SCN7A TDP1 3512/4885SIRT3 288/4885CDC7 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback